R744 clinical traial

Correction and Maintenance study of subcutaneous injections of R744 to predialysis patients (Phase 3, comparative study in comparison with epoetin beta).

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220983

Enrollment

Registered

2010-01-28

Start date

2010-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia

Interventions

investigational material(s) Generic name etc : R744 INN of investigational material : Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal anemia patients before introduction of hemodialysis

Exclusion criteria

Exclusion criteria: Female patients who are pregnant, breastfeeding, possibly pregnant

Design outcomes

Primary

Measure	Time frame
Mean value of Hb concentration Compare with reference drug	—

Secondary

Measure	Time frame
Maintenance rate of Hb concentration Maintenance rate within target range of Hb concentration	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026